Sartorius Kept at Sell as mwb Research Highlights Structural Pressure

06:10 AM EST, 12/12/2025 (MT Newswires) -- Mwb Research maintained its investment opinion on Sartorius (SRT.F), saying the German life science group is facing growing structural headwinds in the US amid legislative efforts to onshore pharmaceutical manufacturing and sharply curb drug prices. "These policies could erode the company's competitive position as demand shifts toward North America, while reduced outsourcing to Asia adds indirect risk. Although short-term US investment activity may offer support, global pharma capex remains weak, particularly in Lab Products & Services. Margin pressure, deglobalization, and limited demand recovery before FY27 weigh on visibility. With the stock trading at 85x 25E and 64x 26E earnings, the valuation remains demanding compared to peers (P/E 26E of 23x). The DCF-based target remains EUR 175.00, the rating SELL," the research firm said in a Thursday note. Mwb projects a 6.6% revenue compound annual growth rate for the 2025 to 2032 period, with an assumed long-term growth rate of 2.5%.